Market Highlights
According to MRFR analysis, Bronchodilators
Market is expected to register a CAGR of 5.30% during the
forecast period of 2019 to 2025 and is expected to reach USD 2,484
Million by 2025.
Bronchodilators are medications that
make breathing easier by opening the airways of the lung by relaxing bronchial
muscles. They are used to treat various respiratory problems such as asthma,
COPD, and other allergic reactions that cause breathing problems.
The growth of the global
bronchodilators market is driven by various factors such as increase in
prevalence of pulmonary disorders, increasing geriatric population and
increasing mergers and acquisitions by prominent players in the market.
However, side effects associated with bronchodilators and government
regulations related to the safety & efficacy of the bronchodilators are
projected to hamper the growth of the global bronchodilators market.
The global bronchodilators market is
currently dominated by several market players. The key players are involved in
product launches and strategic collaborations to strengthen their market
positions. For instance, in April 2019, Cipla Technologies entered into
agreement with Pulmatrix Inc. to co-develop a formulation for the treatment of
allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.
Segmentation
The global bronchodilators market
has been segmented based on drug type, disease, mode of action, and route of
administration.
The market, based on drug type, has
been divided into adrenergic drugs, anticholinergics, a phosphodiesterase
inhibitor, and combination drugs.
The adrenergic segment is likely to
be the largest during the review period as they are the most potent
bronchodilators approved for clinical use in asthma and obstructive lung
disease. The combination drugs segment is predicted to be the fastest-growing
segment. These combination drugs are used if COPD and asthma are not controlled
with monotherapy. These combinations involving two long-acting bronchodilators
with differing modes of action.
The global
bronchodilators market has been segmented, on the basis of disease, into asthma, COPD, and others. The
asthma segment is expected to hold the majority share of the market, owing to
the rise in patients affected with asthma. The COPD segment is expected to be
the fastest-growing as bronchodilators are primary treatment for chronic
obstructive pulmonary disease (COPD) as they help to alleviate bronchial
obstruction and airflow limitation.
In terms of mode of
action, the global bronchodilators market has been segmented into short-acting
bronchodilators and long-acting bronchodilators. Short-acting bronchodilators
are expected to be the largest segment, owing to its ability to provide quick
relief from sudden, unexpected attacks of breathlessness.
The route of administration of the
market is oral and parenteral. The oral route of administration segment is
expected to hold the largest share of the market due to the advantages such as
ease and simplicity of administration along with control of delivered dose.
Key Players
Some of the key players
in the Global Bronchodilators Market are GlaxoSmithKline (UK), Novartis AG (Switzerland),
Merck & Co., Inc. (US), Abbott Laboratories (US), Boehringer Ingelheim GmbH
(Germany), AstraZeneca plc (UK), F. Hoffmann LA-Roche AG (Switzerland), Teva
Pharmaceutical (Israel) and Pfizer Inc. (US) among others.
Regional Analysis
The market has been divided, by
region, into the Americas, Europe, Asia-Pacific, and the Middle East &
Africa. The Americas are expected to be the largest market owing to the rising
per capita healthcare expenditure. The bronchodilators market in the Americas
has further been branched into North America and Latin America, with the North
American market divided into the US and Canada. The European bronchodilators
market has been categorized as Western Europe and Eastern Europe. The Western European
market has further been classified as Germany, France, the UK, Italy, Spain,
and the rest of Western Europe. The bronchodilators market in Asia-Pacific has
been segmented into Japan, China, India, South Korea, Australia, and the rest
of Asia-Pacific. Due to the increasing prevalence of respiratory disorders and
the increasing pool of patient population, the market in Asia-Pacific is
expected to be the fastest-growing. The bronchodilators market in the Middle
East & Africa has been divided into the Middle East and Africa.
No comments:
Post a Comment